Assist Prof Dr. Seyedeh Hoda Alavizadeh | Pharmaceutical Science | Best Researcher Award
Assistant professor at Pharmaceutical Nanotechnology Department, School of Pharmacy, Mashhad University of Medical Sciences, Iran.
Seyedeh Hoda Alavizadeh is an accomplished assistant professor in pharmaceutical nanotechnology at Mashhad University of Medical Sciences, Iran. Her research focuses on innovative drug delivery systems, particularly liposomal formulations for targeted cancer therapy and neurodegenerative diseases. She has a strong academic background with a Pharm.D. and Ph.D. from MUMS, along with numerous honors including fellowships, grants, and awards like being recognized in the top 1% worldwide for her research. Her leadership extends to organizing international conferences and serving as a CRS ambassador. Alavizadeh’s contributions to pharmaceutical sciences are marked by her extensive publication record and active role in international collaborations and editorial activities.
Education 🎓
Seyedeh Hoda Alavizadeh completed her Ph.D. in Pharmaceutical Nanotechnology at the School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Her doctoral research focused on the formulation and characterization of temperature-sensitive nanoliposomal cisplatin targeted with anti-Her-2/neu affibody, investigating its antitumor effects with local hyperthermia in vitro and in vivo using mouse tumor models. Under the guidance of Prof. Mahmoud Reza Jaafari, her work contributed significantly to understanding drug delivery mechanisms in cancer treatment. Prior to her Ph.D., she obtained her Pharm. D. from the same institution, specializing in vaccine delivery against leishmaniasis, supervised by Prof. Ali Khamesipour, Prof. Mahmoud Reza Jaafari, and Dr. Ali Badiee. Her Pharm. D. thesis focused on evaluating immune responses in mice inoculated with L. major mixed with LPD nanoparticles containing CpG ODN, demonstrating her early commitment to innovative pharmaceutical research.
Professional Experience
Since completing her education, Seyedeh Hoda Alavizadeh has served as an Assistant Professor at the Pharmaceutical Nanotechnology Department, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Her interdisciplinary research is grounded in innovation and quality, focusing on developing tumor microenvironment-responsive liposomes for anti-cancer drug delivery. Her expertise includes the formulation of triggered-release liposomes—such as thermo, REDOX, and pH-sensitive formulations—tailored to the tumor microenvironment for cancer therapy and chemo-immunotherapy. She has been actively involved in teaching courses on pharmacy practice, basic biochemistry, biology, cell culture, and advanced topics in drug delivery using nanoparticles.
Research Interest
Seyedeh Hoda Alavizadeh’s research interests are centered on pharmaceutical nanotechnology, with a focus on developing advanced liposomal formulations for targeted drug delivery in cancer therapy. Her research explores triggered-release systems responsive to the tumor microenvironment, including thermo-sensitive, REDOX-sensitive, and pH-sensitive formulations. She is particularly interested in enhancing the efficacy of chemotherapy through innovative liposomal designs and investigating their applications in chemo-immunotherapy. Additionally, she is passionate about developing liposomal formulations of phytochemicals for their antioxidant and neuroprotective roles in diseases like Alzheimer’s and Parkinson’s, contributing to advancements in nanomedicine for therapeutic interventions.
Award and Honors
Seyedeh Hoda Alavizadeh has been recognized with several prestigious honors and awards throughout her career. She served as a CRS Ambassador from 2021 to 2023, promoting excellence in controlled release science. In 2020, she was awarded the Fellowship of the CLINAM Conference and Exhibition, held in Basel, Switzerland, highlighting her contributions to nanomedicine research. Her academic pursuits were further supported by the DAAD Scholarship for the ProGRANT proposal writing course in 2018 and the NIMAD research grant in the same year. Notably, she received the Best Poster Presentation Award at the CLINAM10th Conference and Exhibition in 2017 and was also honored with a Fellowship at the same event, recognizing her impactful research contributions. In 2016, her work was distinguished globally, ranking in the top 1% of papers by Essential Science Indicator of Thomson Reuters ISI, underscoring her significant scholarly impact.
Research Skills
Seyedeh Hoda Alavizadeh possesses a robust skill set in pharmaceutical nanotechnology, focusing on advanced drug delivery systems. Her expertise spans the development of liposomal formulations tailored for targeted delivery of chemotherapeutic agents and phytochemicals, leveraging innovative strategies such as thermo-responsive, REDOX-sensitive, and pH-sensitive mechanisms to optimize drug efficacy while minimizing adverse effects. With a comprehensive understanding of biochemical assays, she proficiently evaluates drug encapsulation efficiencies, release kinetics, and therapeutic outcomes in experimental models. Her academic leadership is evident through roles like vice-scientific chair for the ICNN2021 conference, underscoring her organizational acumen and commitment to advancing nanoscience and nanotechnology. Additionally, her active involvement in international collaborations and editorial responsibilities showcases her dedication to peer-reviewed research and scientific excellence in pharmaceutics and nanomedicine.
Publications
- Bioactivity assessment and toxicity of crocin: a comprehensive review
- Authors: SH Alavizadeh, H Hosseinzadeh
- Year: 2014
- Citations: 422
- Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids
- Authors: M Hatamipour, A Sahebkar, SH Alavizadeh, M Dorri, MR Jaafari
- Year: 2019
- Citations: 102
- Antitumor activity of PEGylated nanoliposomes containing crocin in mice bearing C26 colon carcinoma
- Authors: M Rastgoo, H Hosseinzadeh, H Alavizadeh, A Abbasi, Z Ayati, MR Jaafari
- Year: 2013
- Citations: 90
- Redox-sensitive nanoscale drug delivery systems for cancer treatment
- Authors: E Mirhadi, M Mashreghi, MF Maleki, SH Alavizadeh, L Arabi, A Badiee, …
- Year: 2020
- Citations: 80
- Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA)
- Authors: H Firouzmand, A Badiee, A Khamesipour, VH Shargh, SH Alavizadeh, …
- Year: 2013
- Citations: 63
- Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models
- Authors: SH Alavizadeh, J Akhtari, A Badiee, S Golmohammadzadeh, MR Jaafari
- Year: 2016
- Citations: 56
- Targeting, biodistribution and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors
- Authors: J Akhtari, SM Rezayat, M Teymouri, SH Alavizadeh, F Gheybi, A Badiee, …
- Year: 2016
- Citations: 48
- Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
- Authors: MR Jaafari, M Hatamipour, SH Alavizadeh, A Abbasi, Z Saberi, S Rafati, …
- Year: 2019
- Citations: 46
- The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma
- Authors: SH Alavizadeh, A Badiee, S Golmohammadzadeh, MR Jaafari
- Year: 2014
- Citations: 46
- Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice
- Authors: Z Kavian, SH Alavizadeh, S Golmohamadzadeh, A Badiee, …
- Year: 2019
- Citations: 40
- The molecular mechanisms of curcumin’s inhibitory effects on cancer stem cells
- Authors: E Zendehdel, E Abdollahi, AA Momtazi‐Borojeni, M Korani, …
- Year: 2019
- Citations: 34